Registered title, quoted from ClinicalTrials.gov
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07340398, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Stage I (T1cN0M0)
Inclusion criterion 5
Stage II (T1cN1M0, T2N0-1M0 or T3N0M0)
Inclusion criterion 6
Stage III (T2N2-3M0, T3N1-3M0, or T4N0-3M0)
Inclusion criterion 7
Known hypersensitivity to study drug components; history of immunodeficiency (HIV positive, active HCV, active hepatitis B, other congenital/acquired immunodeficiency) or prior organ transplantation.
Exclusion criterion 9
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Inclusion criterion 2
Hemoglobin ≥100 g/L
Inclusion criterion 11
Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L
Inclusion criterion 12
Platelet count ≥100 × 10⁹/L
Inclusion criterion 13
Total bilirubin ≤1.5 × ULN
Inclusion criterion 15
ALT and AST ≤1.5 × ULN; ALP ≤2.5 × ULN
Inclusion criterion 16
BUN and creatinine ≤1.5 × ULN
Inclusion criterion 17
Breast cancer not confirmed histologically.
Exclusion criterion 4
History of other malignancy within the past 5 years, except successfully treated cervical carcinoma in situ.
Exclusion criterion 5
Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for 8 weeks after the last dose.
Inclusion criterion 19
Pregnant or breastfeeding women, or women of childbearing potential who test positive at baseline or are unwilling to use effective contraception throughout the study.
Exclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07340398, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥18 and ≤75 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Primary tumor size >1 cm.
- Histologically confirmed invasive breast cancer, clinically staged as:
- Stage I (T1cN0M0)
- Stage II (T1cN1M0, T2N0-1M0 or T3N0M0)
- Stage III (T2N2-3M0, T3N1-3M0, or T4N0-3M0)
- HER2-positive status: IHC 3+ or IHC 2+ with positive ISH.
- Adequate major organ function:
- Hematology (no transfusion or hematopoietic growth factors, e.g., G-CSF, within 14 days):
- Hemoglobin ≥100 g/L
- Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L
- Platelet count ≥100 × 10⁹/L
- Biochemistry:
- Total bilirubin ≤1.5 × ULN
- ALT and AST ≤1.5 × ULN; ALP ≤2.5 × ULN
- BUN and creatinine ≤1.5 × ULN
- Cardiac function: LVEF ≥55% by echocardiography
- Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for 8 weeks after the last dose.
- Voluntary written informed consent and willingness to comply with study procedures and follow-up.
Exclusion Criteria:
- Prior anti-tumor therapy for breast cancer, including chemotherapy, radiotherapy, targeted therapy, or endocrine therapy.
- Concurrent administration of any other anti-tumor treatment.
- Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer.
- Breast cancer not confirmed histologically.
- History of other malignancy within the past 5 years, except successfully treated cervical carcinoma in situ.
- Severe dysfunction of major organs (heart, liver, kidney).
- Conditions affecting oral drug administration or absorption, e.g., inability to swallow, chronic diarrhea, or intestinal obstruction.
- Participation in another investigational drug trial within 4 weeks prior to enrollment.
- Known hypersensitivity to study drug components; history of immunodeficiency (HIV positive, active HCV, active hepatitis B, other congenital/acquired immunodeficiency) or prior organ transplantation.
- History of clinically significant cardiac disease, including:
- Arrhythmia requiring medication
- Myocardial infarction
- Heart failure
- Other cardiac conditions deemed unsuitable for study participation by the investigator
- Pregnant or breastfeeding women, or women of childbearing potential who test positive at baseline or are unwilling to use effective contraception throughout the study.
- Any condition that, in the investigator's judgment, poses serious risk to patient safety or may interfere with study completion (e.g., uncontrolled severe hypertension, uncontrolled diabetes, active infection).
- History of neurological or psychiatric disorders (e.g., epilepsy or dementia) or any other condition the investigator considers incompatible with study participation.
Quoted from ClinicalTrials.gov, NCT07340398, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07340398, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.